BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 3257274)

  • 1. Anti-tumor reactivity of human lymphokine activated killer (LAK) cells against fresh and cultured preparations of renal cell cancer.
    Belldegrun A; Uppenkamp I; Rosenberg SA
    J Urol; 1988 Jan; 139(1):150-5. PubMed ID: 3257274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity.
    Belldegrun A; Muul LM; Rosenberg SA
    Cancer Res; 1988 Jan; 48(1):206-14. PubMed ID: 3257161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of lymphokine-activated killer cells and interleukin-2 in treating metastatic renal cell carcinoma.
    Fujioka T; Nomura K; Hasegawa M; Ishikura K; Kubo T
    Br J Urol; 1994 Jan; 73(1):23-31. PubMed ID: 8298895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.
    Grimm EA; Mazumder A; Zhang HZ; Rosenberg SA
    J Exp Med; 1982 Jun; 155(6):1823-41. PubMed ID: 6176669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans.
    Boldt DH; Mills BJ; Gemlo BT; Holden H; Mier J; Paietta E; McMannis JD; Escobedo LV; Sniecinski I; Rayner AA
    Cancer Res; 1988 Aug; 48(15):4409-16. PubMed ID: 3260537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphokine-activated killer (LAK) cell phenomenon. IV. Lysis by LAK cell clones of fresh human tumor cells from autologous and multiple allogeneic tumors.
    Rayner AA; Grimm EA; Lotze MT; Wilson DJ; Rosenberg SA
    J Natl Cancer Inst; 1985 Jul; 75(1):67-75. PubMed ID: 2989604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphokine-activated killer (LAK) cells. Analysis of factors relevant to the immunotherapy of human cancer.
    Rayner AA; Grimm EA; Lotze MT; Chu EW; Rosenberg SA
    Cancer; 1985 Mar; 55(6):1327-33. PubMed ID: 3871657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Depressed ability of patients with melanoma or renal cell carcinoma to generate adherent lymphokine-activated killer cells.
    Sedlmayr P; Rabinowich H; Elder EM; Ernstoff MS; Kirkwood JM; Herberman RB; Whiteside TL
    J Immunother (1991); 1991 Oct; 10(5):336-46. PubMed ID: 1790141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Killing of Fas ligand-resistant renal carcioma cells by interleukin-2- and BCG-activated effector cells.
    Brandau S; Suttmann H; Flad HD; Jocham D; Böhle A
    Cancer Immunol Immunother; 2000 Sep; 49(7):369-76. PubMed ID: 10999463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Usefulness and limitation of immunotherapy of metastatic renal cell carcinoma with autologous lymphokine-activated killer cells and interleukin 2].
    Nakano E; Iwasaki A; Seguchi T; Sugao H; Tada Y; Matsuda M; Sonoda T
    Nihon Hinyokika Gakkai Zasshi; 1991 Mar; 82(3):395-404. PubMed ID: 2072602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice.
    Shiloni E; Lafreniere R; Mulé JJ; Schwarz SL; Rosenberg SA
    Cancer Res; 1986 Nov; 46(11):5633-40. PubMed ID: 3489526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Study of adoptive immunotherapy with lymphokine-activated killer (LAK) cells and interleukin-2 for metastatic renal cell carcinoma. I. Generation of LAK cells by incubation in serum-free medium].
    Nomura K; Fujioka T
    Nihon Hinyokika Gakkai Zasshi; 1993 May; 84(5):822-30. PubMed ID: 8320887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of in vitro lymphokine activated killer (LAK) cell activity against renal cancer cell lines and its suppression by serum factor using crystal violet assay.
    Kanamaru H; Yoshida O
    Urol Res; 1989; 17(4):259-64. PubMed ID: 2788951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy with lymphokine-activated natural killer cells and recombinant interleukin-2: a feasibility trial in metastatic renal cell carcinoma.
    Hercend T; Farace F; Baume D; Charpentier F; Droz JP; Triebel F; Escudier B
    J Biol Response Mod; 1990 Dec; 9(6):546-55. PubMed ID: 2074441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different susceptibilities of lymphokine-activated killer cells (LAK cells) among primary and metastatic renal cell carcinoma derived from the same patient.
    Hattori T; Satoh M; Nishimura T; Kawamura N; Akimoto M
    Br J Urol; 1995 Apr; 75(4):448-51. PubMed ID: 7788254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterogeneity of lymphokine-activated killer cells induced by IL-2. Separate lymphoid subpopulations lyse tumor, allogeneic blasts, and modified syngeneic blasts.
    LeFor AT; Eisenthal A; Rosenberg SA
    J Immunol; 1988 Jun; 140(11):4062-9. PubMed ID: 3259603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Local administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with malignant brain tumors.
    Yoshida S; Tanaka R; Takai N; Ono K
    Cancer Res; 1988 Sep; 48(17):5011-6. PubMed ID: 3261631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
    Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
    J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo and ex vivo antitumor activity in patients receiving low-dose subcutaneous recombinant interleukin-2.
    Schomburg A; Menzel T; Körfer A; Heer G; Dallmann I; Kirchner H; Poliwoda H; Atzpodien J
    Nat Immun; 1992; 11(3):133-43. PubMed ID: 1392401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant interleukin-2-expanded tumor infiltrating lymphocytes from human renal cell cancer do not exhibit autologous tumor cell-specific cytotoxicity.
    Nishimura T; Terashima Y; Hattori T; Satoh M; Kondo Y; Kimura G; Yoshida K; Akimoto M
    Urol Int; 1991; 47 Suppl 1():83-5. PubMed ID: 1949387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.